Could blood marker predict the risk of osteoporotic hip fracture in men?
Written By : Isra Zaman
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-08-18 04:15 GMT | Update On 2022-08-18 04:15 GMT
In new research published in the Journal of Bone and Mineral Research, elevated blood levels of a certain chemokine, or small signaling protein, that promotes osteoclast formation were linked with a higher risk of hip fracture in men.The study included 55 men and 119 women who had experienced a hip fracture an average of 6.3 years after their blood was collected. The participants were...
Login or Register to read the full article
In new research published in the Journal of Bone and Mineral Research, elevated blood levels of a certain chemokine, or small signaling protein, that promotes osteoclast formation were linked with a higher risk of hip fracture in men.
The study included 55 men and 119 women who had experienced a hip fracture an average of 6.3 years after their blood was collected. The participants were matched individually to controls who did not develop hip fractures.
Investigators observed higher blood levels of the chemokine CXCL9 in the pre-fracture blood samples of men with subsequent hip fractures compared with their non-fracture controls. No such difference was seen in women.
"The unexpected difference in the results between men and women in our study may be explained by how changes in sex hormone levels during aging could influence the level and effects of CXCL9 differently in older men and women," explained corresponding author Woon-Puay Koh from the National University of Singapore (NUS).
"Our findings open the exciting possibility that early interventions targeting CXCL9 or CXCL9-CXCR3 signaling could be beneficial in preventing hip fractures in older men," added co-corresponding author Christoph Winkler.
Ref: Woon-Puay Koh et. al,CXCL9 predicts the risk of osteoporotic hip fracture in a prospective cohort of Chinese men,Journal of Bone and Mineral Research,10.1002/jbmr.4646
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd